Presentation is loading. Please wait.

Presentation is loading. Please wait.

Combination of R848 and anti-CD200R affects activation of tumor-infiltrating myeloid cells. Combination of R848 and anti-CD200R affects activation of tumor-infiltrating.

Published byŁucja Zalewska Modified over 4 years ago

Similar presentations

Presentation on theme: "Combination of R848 and anti-CD200R affects activation of tumor-infiltrating myeloid cells. Combination of R848 and anti-CD200R affects activation of tumor-infiltrating."— Presentation transcript:

1 Combination of R848 and anti-CD200R affects activation of tumor-infiltrating myeloid cells.
Combination of R848 and anti-CD200R affects activation of tumor-infiltrating myeloid cells. Single-cell suspensions of CT26 tumors were analyzed by flow cytometry (24 hours after the therapy). Percentage of viable immune cells CD45.2+ (A) and nonimmune cells (B). C, Percentage of intratumoral myeloid cells (CD11b+). Expression of macrophage markers was analyzed in the CD11b+ cell population: (D) CD206, (E) CD86, (F) CD115, (G) F4/80, n = 8–9. H, Examples of expression of the F4/80, CD206, CD86, and CD115 in R848/anti-CD200R and control mice. I, Production of IL1β in intratumoral CD11b+ cell, upon stimulation with LPS, n = 8–9. J, Examples of IL1β expression in all treatment groups. A–H, Reproduced two times. I and J, Performed once. When not indicated otherwise, significance was calculated in comparison with the PBS-only control group using one-way ANOVA. *, P < 0.05; ** P < 0.01; ***, P < Zofia Pilch et al. Cancer Immunol Res 2018;6: ©2018 by American Association for Cancer Research

Download ppt "Combination of R848 and anti-CD200R affects activation of tumor-infiltrating myeloid cells. Combination of R848 and anti-CD200R affects activation of tumor-infiltrating."

Similar presentations

Figure 3. TLT-6 expressions in hematopoietic stem cells, monocyts and macrophages. (A) Expression patterns of TLT-6 in the surface of hematopoietic lineage.

Figure 3. TLT-6 expressions in hematopoietic stem cells, monocyts and macrophages. (A) Expression patterns of TLT-6 in the surface of hematopoietic lineage.
Synergistic antitumor effect of anti-CD40/CpG and 14

Synergistic antitumor effect of anti-CD40/CpG and 14
Identification of combination treatment–responsive effector/memory tumor-infiltrating CD8+ T cell population. Identification of combination treatment–responsive.

Identification of combination treatment–responsive effector/memory tumor-infiltrating CD8+ T cell population. Identification of combination treatment–responsive.
Identification of combination treatment–responsive dysfunctional tumor-infiltrating CD8+ T cell population. Identification of combination treatment–responsive.

Identification of combination treatment–responsive dysfunctional tumor-infiltrating CD8+ T cell population. Identification of combination treatment–responsive.
Resveratrol modulates DSS-induced neutrophils during colitis.

Resveratrol modulates DSS-induced neutrophils during colitis.
Anti–4-1BB/PD-1 combination enriched CD8+ T cells in TILs

Anti–4-1BB/PD-1 combination enriched CD8+ T cells in TILs
Human NK cell development in NOD/SCID mice receiving grafts of cord blood CD34+ cells by Christian P. Kalberer, Uwe Siegler, and Aleksandra Wodnar-Filipowicz.

Human NK cell development in NOD/SCID mice receiving grafts of cord blood CD34+ cells by Christian P. Kalberer, Uwe Siegler, and Aleksandra Wodnar-Filipowicz.
Attenuated MDSC-suppressive activity and metastasis development in IDO-deficient mice is rescued by IL-6. Attenuated MDSC-suppressive activity and metastasis.

Attenuated MDSC-suppressive activity and metastasis development in IDO-deficient mice is rescued by IL-6. Attenuated MDSC-suppressive activity and metastasis.
Sunitinib plus rMVA–CEA–TRICOM vaccine decreased tumor burden and increased intratumoral infiltration of T lymphocytes in the MC38-CEA colon carcinoma.

Sunitinib plus rMVA–CEA–TRICOM vaccine decreased tumor burden and increased intratumoral infiltration of T lymphocytes in the MC38-CEA colon carcinoma.
Frequencies of immune cell types show much stronger variations between tumor types in the tumor infiltrate compared with the spleen and tumor-draining.

Frequencies of immune cell types show much stronger variations between tumor types in the tumor infiltrate compared with the spleen and tumor-draining.
Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.

Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.
Gr-1+ MDSC in tumor-bearing mice produce IL-6.

Gr-1+ MDSC in tumor-bearing mice produce IL-6.
Increased chemokine content and leukocyte infiltrate in D6-negative tumors. Increased chemokine content and leukocyte infiltrate in D6-negative tumors.

Increased chemokine content and leukocyte infiltrate in D6-negative tumors. Increased chemokine content and leukocyte infiltrate in D6-negative tumors.
TANs mediate obesity-induced tumor progression and aggravated desmoplasia. TANs mediate obesity-induced tumor progression and aggravated desmoplasia. A,

TANs mediate obesity-induced tumor progression and aggravated desmoplasia. TANs mediate obesity-induced tumor progression and aggravated desmoplasia. A,
Epithelial loss of TβRII results in increased Th17 cell development.

Epithelial loss of TβRII results in increased Th17 cell development.
CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.

CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.
Immune cell recruitment after the NIR-boosted and MN-mediated cancer immunotherapy. Immune cell recruitment after the NIR-boosted and MN-mediated cancer.

Immune cell recruitment after the NIR-boosted and MN-mediated cancer immunotherapy. Immune cell recruitment after the NIR-boosted and MN-mediated cancer.
PD1 targeting alters the recruitment of immune cells to MC38 CRC tumors. PD1 targeting alters the recruitment of immune cells to MC38 CRC tumors. MC38.

PD1 targeting alters the recruitment of immune cells to MC38 CRC tumors. PD1 targeting alters the recruitment of immune cells to MC38 CRC tumors. MC38.
Treatment of ob/ob mice with TTR-ASOs reduces adipose tissue inflammation. Treatment of ob/ob mice with TTR-ASOs reduces adipose tissue inflammation. A:

Treatment of ob/ob mice with TTR-ASOs reduces adipose tissue inflammation. Treatment of ob/ob mice with TTR-ASOs reduces adipose tissue inflammation. A:
Diclofenac treatment reduces L-selectin on peripheral blood and infiltrated leukocytes but does not alter accumulation in the injured spinal cord. Diclofenac.

Diclofenac treatment reduces L-selectin on peripheral blood and infiltrated leukocytes but does not alter accumulation in the injured spinal cord. Diclofenac.

Similar presentations

Ads by Google